In:
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Vol. 46, No. 9 ( 2002-09), p. 3071-3074
Kurzfassung:
The in vitro and in vivo activities of DW286, a novel fluoronaphthyridone with potent antibacterial activity, were compared with those of ciprofloxacin, gemifloxacin, sparfloxacin, and trovafloxacin. Against gram-positive bacteria, such as Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pneumoniae , and Enterococcus faecalis , the in vitro activity of DW286 was stronger than that of any other reference antibiotic. Against gram-negative bacteria, the activity of DW286 was similar to those of trovafloxacin and gemifloxacin but was weaker than that of ciprofloxacin. In a mouse systemic infection caused by three S. aureus strains, including methicillin-resistant S. aureus and quinolone-resistant S. aureus (QRSA), DW286 demonstrated the most potent activity, as found in vitro. Specially, DW286 is ≥8-fold more active against QRSA than the other fluoroquinolones. And the 50% protective doses for DW286 were correspondent with the in vitro activities.
Materialart:
Online-Ressource
ISSN:
0066-4804
,
1098-6596
DOI:
10.1128/AAC.46.9.3071-3074.2002
Sprache:
Englisch
Verlag:
American Society for Microbiology
Publikationsdatum:
2002
ZDB Id:
1496156-8
SSG:
12
SSG:
15,3
